140 related articles for article (PubMed ID: 3857159)
1. [Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
Heptner G; Domschke S; Schneider MU; Domschke W
Dtsch Med Wochenschr; 1985 Apr; 110(16):624-8. PubMed ID: 3857159
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
Blind PJ; Dahlgren ST
Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
[TBL] [Abstract][Full Text] [Related]
3. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.
Harmenberg U; Wahren B; Wiechel KL
Cancer Res; 1988 Apr; 48(7):1985-8. PubMed ID: 3349472
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
Safi F; Büchler M; Schenkluhn B; Beger HG
Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma].
Nouts A; Lévy P; Voitot H; Bernades P
Gastroenterol Clin Biol; 1998 Feb; 22(2):152-9. PubMed ID: 9762189
[TBL] [Abstract][Full Text] [Related]
6. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
Röthlin M; Metzger U; Joller H; Largiadèr F
Schweiz Med Wochenschr; 1988 Jun; 118(24):924-9. PubMed ID: 2456610
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
8. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
Hyöty M; Hyöty H; Aaran RK; Airo I; Nordback I
Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of CA 50 and CA 19-9 tumor markers in benign and malignant diseases of the upper gastrointestinal tract].
Heptner G; Domschke S; Schneider MU; Siegfried W; Domschke W
Dtsch Med Wochenschr; 1986 Mar; 111(10):374-8. PubMed ID: 2419074
[TBL] [Abstract][Full Text] [Related]
10. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
[TBL] [Abstract][Full Text] [Related]
11. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
12. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K
Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
Ohkura H; Sakawaki T
Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
[TBL] [Abstract][Full Text] [Related]
16. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
17. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon].
Klapdor R; Klapdor U; Bahlo M; Dallek M; Kremer B; van Ackeren H; Schreiber HW; Greten H
Dtsch Med Wochenschr; 1984 Dec; 109(51-52):1949-54. PubMed ID: 6595110
[TBL] [Abstract][Full Text] [Related]
18. How does liver dysfunction influence serum CA 19-9 in pancreatic cancer?
Basso D; Fabris C; Del Favero G; Piccoli A; Angonese C; Pasquali C; Castoro C; Plebani M; Leandro G; Burlina A
Ital J Gastroenterol; 1990 Feb; 22(1):1-6. PubMed ID: 2131920
[TBL] [Abstract][Full Text] [Related]
19. [Serum tissue polypeptide antigen in the differential diagnosis of chronic pancreatitis and exocrine pancreatic tumors. Preliminary results].
Ruibal A; Encabo G
Rev Esp Oncol; 1983; 30(3):313-6. PubMed ID: 6571374
[TBL] [Abstract][Full Text] [Related]
20. [Attention to CA 19.9 in alcoholics. Apropos of a case].
Giovannini M; Penalvert F; Maillot A; Escoffier JM; Botta D; Gauthier A
Ann Gastroenterol Hepatol (Paris); 1987 Dec; 23(7):393. PubMed ID: 3481241
[No Abstract] [Full Text] [Related]
[Next] [New Search]